Kyowa Kirin Co Ltd (KY4.MU)
| Previous close | 15.50 |
| Open | 15.90 |
| Bid | 16.00 x 0 |
| Ask | 16.70 x 0 |
| Day's range | 15.90 - 15.90 |
| 52-week range | 13.90 - 18.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireKyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE: 4151), a global specialty pharmaceutical company based in Japan, today announced that its board of directors has approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, North Carolina. The 171,700-square-foot, two-reactor facility will accelerate the company's development and production of biologic therapies for patients with rare and serious diseases while also co
PR NewswireKyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.
Business WireFirst Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
TOKYO, April 15, 2024--On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, "Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)", a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subt
